|
| Press Releases |
|
 |
|
| Thursday, July 26, 2018 |
|
|
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at AAIC 2018 |
| Eisai Co., Ltd. and Biogen Inc. announced detailed results from the Phase II study (Study 201) with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease as part of Session DT-01 "Recent Developments in Therapeutics" at AAIC 2018 being held in Chicago, Illinois, United States on July 25. more info >> |
|
|
Eisai and Biogen Present Detailed Results from Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at AAIC 2018 |
| Eisai Co., Ltd. and Biogen Inc. announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE inhibitor elenbecestat (development code: E2609) at the AAIC 2018 being held in Chicago, Illinois, United States, from July 22 to 26, 2018. more info >> |
|
| Thursday, July 19, 2018 |
|
|
Latest Data on Eisai's Alzheimer's Disease / Dementia Pipeline to be Presented at Alzheimer's Association International Conference (AAIC) 2018 |
| Eisai Co., Ltd. announces today that a total of 13 presentations highlighting results from a Phase II clinical study (Study 201) of the anti-amyloid beta (Abeta) protofibril antibody BAN2401 and a Phase II clinical study (Study 202) will be given at the Alzheimer's Association International Conference (AAIC) 2018, in Chicago. more info >> |
|
| Wednesday, July 18, 2018 |
|
|
Eisai: Positive Topline Results Obtained from Large-Scale Cardiovascular Outcomes Trial of Anti-Obesity Agent BELVIQ |
| This study was conducted at over 400 sites in eight countries including the United States in collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, and is the largest cardiovascular outcome trial conducted to date for a weight loss medication. more info >> |
|
| Wednesday, July 11, 2018 |
|
|
Eisai: Oral Antifungal Agent Nailin Capsules 100mg to be Launched in Japan |
| Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. will launch the oral antifungal agent NAILIN Capsules 100mg in Japan on July 27, 2018. more info >> |
|
| Tuesday, July 10, 2018 |
|
|
Eisai: Oral Presentation on Phase II Clinical Study Results of BAN2401 to be Presented at Alzheimer's Association International Conference (AAIC) 2018 |
| Eisai Co., Ltd. announces today that the results of the Phase II clinical study (Study 201) of the anti-amyloid beta (Abeta) protofibril antibody BAN2401 will be presented in an oral session at the Alzheimer's Association International Conference (AAIC) 2018 held in Chicago. more info >> |
|
| Monday, July 9, 2018 |
|
|
Eisai: Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment "GOOFICE 5mg Tablet" Published in The Lancet Gastroenterology & Hepatology |
| The 2-week double-blind clinical trial was a placebo-controlled, randomized, double-blind trial with 133 Japanese patients with chronic constipation. more info >> |
|
| Friday, July 6, 2018 |
|
|
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 At 18 Months |
| Eisai Co., Ltd. and Biogen Inc. announced positive topline results from the Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease. more info >> |
|
| Wednesday, July 4, 2018 |
|
|
Eisai Listed for 17th Consecutive Year in FTSE4GOOD Index Series |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 17th consecutive year since its initial inclusion in 2002. more info >> |
|
| Monday, July 2, 2018 |
|
|
Eisai to Give Oral Presentation on Results of Phase III Head-to-Head Clinical Study of Lemborexant in Insomnia Disorder |
| The symposium will report on the latest data on lemborexant from non-clinical research and clinical studies relating to insomnia, including the results of SUNRISE 1. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
MHIEC Receives Contract for Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kanazawa
Oct 16, 2025 23:57 JST
|
|
|
Canada Backs Advanced Tokenization and Distributed Federated Learning Research with Over $3 Million in Funding
Oct 16, 2025 22:45 HKT/SGT
|
|
|
Overview of Honda Exhibits at Japan Mobility Show 2025
Oct 16, 2025 23:20 JST
|
|
|
DENSO to Exhibit at JAPAN MOBILITY SHOW 2025
Oct 16, 2025 22:53 JST
|
|
|
Fujitsu and IISc launch joint research on advanced AI technologies to accelerate new material development and resolve societal challenges
Oct 16, 2025 21:55 JST
|
|
|
Kincora Appoints Kerry Stevenson and Michelle Borromeo to the Advisory Board
Oct 16, 2025 20:09 HKT/SGT
|
|
|
45th Electronics Fair and electronicAsia attract some 60,000 buyers
Oct 16, 2025 19:06 HKT/SGT
|
|
|
Radisson Expands Ongoing Step-Out Drill Program at O'Brien to 140,000 Metres
Oct 16, 2025 18:39 HKT/SGT
|
|
|
How DPC Dash-Domino's Pizza China Is Capturing China's Pizza Market
Oct 16, 2025 14:30 HKT/SGT
|
|
|
SERES Passes HKEX Listing Hearing - First 'A+H' Dual-Listed Premium NEV Maker Poised for Hong Kong Debut
Oct 16, 2025 14:28 HKT/SGT
|
|
|
Owkin Launches K Pro: The First Agentic AI Co-Pilot for Biopharma Powered by Biological Reasoning Models
Oct 16, 2025 13:00 HKT/SGT
|
|
|
Ceramics & Natural Stone Manufacturers Converge in Bangkok for ASEAN Ceramics & ASEAN Stone 2025
Oct 16, 2025 12:00 HKT/SGT
|
|
|
Discover the Secret to Your Best You Through Silica-Rich Hydration with Spritzer Natural Mineral Water
Oct 15, 2025 20:30 HKT/SGT
|
|
|
Mitsubishi Motors Wins Triple Honors at Good Design Award 2025 in Japan with the Delica Mini, Destinator and Delica Series
Oct 15, 2025 21:29 JST
|
|
|
Mitsubishi Motors at Japan Mobility Show 2025: World Premiere of Electrified Crossover SUV Concept
Oct 15, 2025 20:35 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
